Schrodinger (SDGR) said Monday it plans to launch its predictive toxicology tool to customers in H2.
The computational tool is targeted to improve the properties of drug development candidates and lessen the risk of development failure related to binding off-target proteins, the company said.
The tool is in line with the plan of the US Food and Drug Administration to wind down animal testing requirement for monoclonal antibodies and other drugs, the company said.
"We believe our computational solutions will play a vital role in significantly reducing the use of animal models in preclinical development," Schrodinger CEO Ramy Farid said.
Price: 25.76, Change: +1.27, Percent Change: +5.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.